Below are extracts from the emergency use application for the Pfizer “vaccine” you will see, that, this is a dangerous shot with no knowledge of any long term dangers. While reading thru the many charts I found very little good compared to the placebo. The shot v placebo provides more complications. There are also some doubts as to effectiveness by the board.
[ vak-seen or, especially British, vak-seen, -sin ]SHOW IPA
any preparation used as a preventive inoculation to confer immunity against a specific disease, usually employing an innocuous form of the disease agent, as killed or weakened bacteria or viruses, to stimulate antibody production.
the virus of cowpox, used in vaccination, obtained from pox vesicles of a cow or person.
a software program that helps to protect against computer viruses, as by detecting them and warning the user.
Messenger RNA (mRNA)
Messenger RNA (mRNA) is a single-stranded RNA molecule that is complementary to one of the DNA strands of a gene. The mRNA is an RNA version of the gene that leaves the cell nucleus and moves to the cytoplasm where proteins are made. During protein synthesis, an organelle called a ribosome moves along the mRNA, reads its base sequence, and uses the genetic code to translate each three-base triplet, or codon, into its corresponding amino acid.
(emphasis added by me)
from the EUA
- Executive Summary
On November 20, 2020, the Sponsor (Pfizer, on behalf of Pfizer and BioNTech) submitted an Emergency Use Authorization (EUA) request to FDA for an investigational COVID-19 vaccine
(BNT162b2) intended to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine is based on the SARS-CoV-2 spike glycoprotein (S)
antigen encoded by RNA and formulated in lipid nanoparticles (LNPs). The proposed use under an EUA is “for active immunization for the prevention of COVID-19 caused by SARS-CoV-2 in
individuals 16 years of age and older.” The proposed dosing regimen is 2 doses, 30 µg each, administered 21 days apart.
• The chemical, biological, radiological, or nuclear (CBRN) agent referred to in the March 27, 2020, EUA declaration by the Secretary of HHS (SARS-CoV-2) can cause a
serious or life-threatening disease or condition.
2.3. EUA Request for the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)
Pfizer, in partnership with BioNTech Manufacturing GmbH, is developing a vaccine to prevent
COVID-19 which is based on the SARS-CoV-2 spike glycoprotein (S) antigen encoded by RNA and formulated in lipid nanoparticles (LNP). The Pfizer-BioNTech COVID-19 Vaccine (also
referred to as BNT162b2) is administered intramuscularly as a 2-dose series spaced 21 days apart at a dose of 30 µg each. The vaccine is supplied as a multi-dose vial (5 doses) containing
a frozen suspension (-80°C to -60°C) of BNT162b2 that must be thawed and diluted with 1.8 mL of sterile 0.9% sodium chloride, allowing for five 0.3 mL doses. The vaccine is preservative free.
3.1. Vaccine Composition, Dosing Regimen
The Pfizer-BioNTech COVID-19 Vaccine is a white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection. The vaccine contains a nucleoside-modified messenger
RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. The vaccine also includes the following ingredients: lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-
hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-snglycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium
phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.
(wow thats a lot of crap in that shot, including the chemical used to put people to death)
The Pfizer-BioNTech COVID-19 Vaccine is supplied as a frozen [between -80°C to -60°C (-
112°F to -76°F)] multi-dose (5-dose) vial. The vaccine must be thawed and diluted in its original
vial with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP prior to administration. After
dilution, the vial contains 5 doses of 0.3 mL per dose. After dilution, the multiple-dose vials must
be stored between 2°C to 25°C (35°F to 77°F) and used within 6 hours from the time of dilution.
Reactogenicity data from a total of 100
adolescents 12 through 15 years of age enrolled in C4591001 Phase 2/3 were provided in the
EUA submission. However, the Sponsor did not request inclusion of this age group in the EUA
because the available data, including number of participants and follow-up duration, were
Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum insufficient to support favorable a benefit-risk determination at this time. Therefore, the reactogenicity data for participants 12 through 15 years of age are not presented in this
Suspected COVID-19 Cases
As specified in the protocol, suspected cases of symptomatic COVID-19 that were not PCRconfirmed were not recorded as adverse events unless they met regulatory criteria for seriousness. Two serious cases of suspected but unconfirmed COVID-19 were reported, both in the vaccine group, and narratives were reviewed. In one case, a 36-year-old male with no
medical comorbidities experienced fever, malaise, nausea, headache and myalgias beginning on the day of Dose 2 and was hospitalized 3 days later for further evaluation of apparent infiltrates on chest radiograph and treatment of dehydration. A nasopharyngeal PCR test for SARS-CoV-2 was negative on the day of admission, and a chest CT was reported as normal.
The participant was discharged from the hospital 2 days after admission. With chest imaging findings that are difficult to reconcile, it is possible that this event represented reactogenicity
following the second vaccination, a COVID-19 case with false negative test that occurred less than 7 days after completion of the vaccination series, or an unrelated infectious process.
In the other case, a 66-year-old male with no medical comorbidities experienced fever, myalgias, and shortness of breath beginning 28 days post-Dose 2 and was hospitalized one day later with
abnormal chest CT showing a small left-sided consolidation. He was discharged from the hospital 2 days later, and multiple nasopharyngeal PCR tests collected over a 10-day period
beginning 2 days after symptom onset were negative. It is possible, though highly unlikely, that this event represents a COVID-19 case with multiple false negative tests that occurred more
than 7 days after completion of the vaccination regimen, and more likely that it represents an unrelated infectious process
Among 3,410 total cases of suspected but unconfirmed COVID-19 in the overall studypopulation, 1,594 occurred in the vaccine group vs. 1816 in the placebo group. Suspected
COVID-19 cases that occurred within 7 days after any vaccination were 409 in the vaccine
group vs. 287 in the placebo group. It is possible that the imbalance in suspected COVID-19
cases occurring in the 7 days postvaccination represents vaccine reactogenicity with symptoms
that overlap with those of COVID-19. Overall though, these data do not raise a concern that
protocol-specified reporting of suspected, but unconfirmed COVID-19 cases could have masked
clinically significant adverse events that would not have otherwise been detected.
Vaccine effectiveness against long-term effects of COVID-19 disease
COVID-19 disease may have long-term effects on certain organs, and at present it is not possible to assess whether the vaccine will have an impact on specific long-term sequelae of
COVID-19 disease in individuals who are infected despite vaccination. Demonstrated high efficacy against symptomatic COVID-19 should translate to overall prevention of COVID-19-
related sequelae in vaccinated populations, though it is possible that asymptomatic infections
may not be prevented as effectively as symptomatic infections and may be associated with
sequelae that are either late-onset or undetected at the time of infection (e.g., myocarditis).
Additional evaluations will be needed to assess the effect of the vaccine in preventing long-term
effects of COVID-19, including data from clinical trials and from the vaccine’s use post authorization.
A numerically greater number of appendicitis cases occurred in the vaccine group but occurred
no more frequently than expected in the given age groups and do not raise a clear concern at
this time for a causal relationship to study vaccination. Although the safety database revealed
an imbalance of cases of Bell’s palsy (4 in the vaccine group and none in the placebo group),
causal relationship is less certain because the number of cases was small and not more
frequent than expected in the general population. Further signal detection efforts for these
adverse events will be informative with more widespread use of the vaccine.
Some pointed out the importance of long-term safety data for the PfizerBioNTech COVID-19 Vaccine as it is made using a technology not used in previously licensed vaccines.
The lack of data on how the vaccine impacts asymptomatic infection and viral shedding was
also pointed out and that this should be addressed prior to study unblinding. Other committee
members were concerned about limited data available in certain subpopulations such as HIVinfected individuals, individuals with prior exposure to SARS-CoV-2 and certain demographic
Reports of lymphadenopathy were imbalanced with notably more cases in the vaccine group
(64) vs. the placebo group (6), which is plausibly related to vaccination. Bell’s palsy was
reported by four vaccine participants and none in the placebo group.